The effect of metformin on reducing preeclampsia
Phase 3
Recruiting
- Conditions
- Pre-eclampsia.Pre-eclampsia
- Registration Number
- IRCT20191104045328N14
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 80
Inclusion Criteria
Pregnant mothers with low pregnancy-related plasma protein A referred to kousar Clinic
Normal arterial Doppler ultrasound
Age 18-50 years
Consent to participate in the study
Exclusion Criteria
History of intrauterine growth restriction or preeclampsia, gestational hypertension or pregnancy complications in previous pregnancies
History of congenital disease
History of liver or kidney failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Functional liver enzymes. Timepoint: in the 14th, 28th, 32nd weeks of pregnancy and at the time of delivery. Method of measurement: laboratory test.;Systolic and diastolic blood pressure. Timepoint: in the 14th, 28th, 32nd weeks of pregnancy and at the time of delivery. Method of measurement: Mercury sphygmomanometer.;Proteinuria. Timepoint: in the 14th, 28th, 32nd weeks of pregnancy and at the time of delivery. Method of measurement: Urinalysis test.;Preterm delivery. Timepoint: Delivery between 20 and 37 weeks. Method of measurement: Delivery.;Low birth weight. Timepoint: Birth weight less than 2500 grams. Method of measurement: scales.;Type of delivery. Timepoint: How the baby is born. Method of measurement: Cesarean-vaginal.
- Secondary Outcome Measures
Name Time Method